Comparison of two different dosage of GnRH agonist as ovulation trigger in oocyte donors: a randomized controled trial

Abstract

Objective: To compare the results obtained with two different GnRH agonist dosages: 0.3mg versus 0.4mg to trigger ovulation in oocyte donor cycles.Methods: Experimental controlled randomized trial including 40 patients from a private practice center. The patients were randomized into two groups. Group A received a single dose of Triptorelin 0.3mg (Decapeptyl ® ) 36 hours before pick-up. Group B patients received Triptorelin 0.4mg (Decapeptyl ® ) before pick-up to final oocyte maturation. We evaluated the total number of oocytes collected, the number of mature oocytes and total days of ovarian stimulation.Results: The average of total collected oocytes were 16 (Group A) versus 15 (Group B), and the mean number of mature oocytes were 13 versus 12 respectively. The only variable showing a difference was the percentage of mature oocytes, which was greater in Group A, resulting in 84.6%, in contrast with those treated with 0.4mg of Triptorelin (78.6%), although these differences were not statistical significant (p=0.35). Days of stimulation did not differ between groups. No cases of empty follicle syndrome were reported.Conclusions: We found that an increase from 0.3 to 0.4mg of triptorelin in an oocyte donation program might not improve outcomes. Nevertheless, more studies might be necessary, not only in oocyte donors but in sterile women as well, to evaluate how GnRH agonist dosage could affect the results among other factors.

Gonadotropin-releasing hormone agonist (alone or combined with human chorionic gonadotropin) vs. human chorionic gonadotropin alone for ovulation triggering during controlled ovarian stimulation for in vitro fertilization/intracytoplasmic sperm injection: a systematic review and meta-analysis

“…Numerous GnRHa formulations are available, and the optimal dose and route of administration have not been established. Very few studies have investigated the optimal GnRHa dose to obtain oocyte maturation, and no differences were noted between treatments with triptorelin 0.1, 0.2, and 0.3 mg (135); leuprolide acetate 1 and 2 mg (136); triptorelin 0.2, 0.3, and 0.4 mg (137); and triptorelin 0.3 and 0.4 mg (138). Similarly, in our study with a different protocol for GnRHa triggering (triptorelin 0.3, 0.2, or 0.1 mg; buserelin 0.5 or 0.2 mg; or leuprorelin 1, 0.5, or 0.15 mg), no difference was found regarding our primary objectives: number of retrieved oocytes; number of metaphase II oocytes; or maturation rate.…”